Jyoti Malhotra

Jyoti Malhotra

Medical Oncologist

Тhoracic oncology

City of Hope

Location USA, Duarte

Dr. Jyoti Malhotra is a thoracic medical oncologist specializing in lung cancer and early-phase clinical trials. Her work focuses on precision medicine, immunotherapy, and the development of novel cancer therapeutics, with extensive leadership in investigator-initiated and first-in-human studies.

Current Position

  • Interim Division Chief, Thoracic Medical Oncology, City of Hope, Duarte, USA
  • Director, Thoracic Medical Oncology, City of Hope Orange County, USA
  • Associate Professor, Department of Medical Oncology & Therapeutics Research, City of Hope

Education

  • MPH, Johns Hopkins Bloomberg School of Public Health (2006)
  • MD (MBBS), University of Delhi (2005)
  • Residency in Internal Medicine, Georgetown University Hospital / Washington Hospital Center
  • Fellowship in Hematology & Oncology, Icahn School of Medicine at Mount Sinai (2012–2015)

Area of Specialization

  • Thoracic oncology
  • Lung cancer and mesothelioma
  • Early-phase (Phase I) clinical trials
  • Precision medicine
  • Immunotherapy

Professional Experience

  • Associate Professor, Robert Wood Johnson Medical School
  • Attending Physician, Rutgers Cancer Institute of New Jersey
  • Instructor, Memorial Sloan Kettering Cancer Center

Research & Clinical Activity

  • Leader in early-phase and experimental therapeutics programs
  • Institutional principal investigator on 50+ clinical trials
  • Led 10+ investigator-initiated trials, including first-in-human studies
  • Research in immunotherapy resistance and biomarker-driven therapies

Publications

  • Author of 100+ peer-reviewed publications in oncology
  • Contributions to lung cancer genomics, immunotherapy, and clinical trial development

Leadership & Memberships

  • Contributor to NCCN Clinical Practice Guidelines (Small Cell Lung Cancer)
  • Member, American Society of Clinical Oncology (ASCO)
  • Member, American Association for Cancer Research (AACR)
  • Member, International Association for the Study of Lung Cancer (IASLC)

All information is sourced from publicly available materials.